Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study
Mood fluctuations related to levodopa (LD) dosing are well‐known psychiatric complications of Parkinson's disease (PD). No formal studies explored how affective response to LD relates to the type of motor response to oral LD (stable or wearing‐off) and to different pharmacokinetic profiles of o...
Gespeichert in:
| Veröffentlicht in: | Movement disorders 2007-01, Vol.22 (1), p.62-67 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 67 |
|---|---|
| container_issue | 1 |
| container_start_page | 62 |
| container_title | Movement disorders |
| container_volume | 22 |
| creator | Kulisevsky, Jaime Pascual-Sedano, Berta Barbanoj, Manel Gironell, Alexandre Pagonabarraga, Javier García-Sánchez, Carmen |
| description | Mood fluctuations related to levodopa (LD) dosing are well‐known psychiatric complications of Parkinson's disease (PD). No formal studies explored how affective response to LD relates to the type of motor response to oral LD (stable or wearing‐off) and to different pharmacokinetic profiles of oral LD. We used an intrasubject randomized double‐blind crossover design to study 14 patients (7 stable, 7 wearing‐off) who were monitored for motor status, mood, anxiety, and plasma LD levels 1 hour before and 6 hours after an oral dose of immediate‐release (IR) and controlled‐release LD formulations. Analysis of the dose–response curves showed a significant interaction between the type of motor response and the type of LD. Only the wearing‐off patients had a significant mood elevation, and this effect was only significant following challenge with IR LD. Motor status strongly correlated with LD plasma levels and anxiety but not with mood ratings. Mood changes in PD patients are related to the patient's type of motor response to oral LD and also to the kinetic profile of the LD formulation used for dopaminergic replacement. © 2006 Movement Disorder Society |
| doi_str_mv | 10.1002/mds.21205 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68951659</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21158720</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4885-4b3fd48b6573a34a1d7cf5c8ee7161ee371d16df5dba75cff9b85e3beb75f5373</originalsourceid><addsrcrecordid>eNqFkUFvEzEQhS1ERUPhwB9AvgDisK29Xq-d3kKhKVJTKhHE0fLaY8ngXQd7F8i_x2lCe0KcZjT65s3oPYReUHJKCanPeptPa1oT_gjNKGe0kjUXj9GMSMkrRiU_Rk9z_kYIpZy2T9AxFaVjUs5QXJhpBAzOgRkzjg77vgfrdRnqwWIThzHFEMBWCQLoDDjAz2jjRuM44D5Gi_2Ab3X67occhzcZW5933DleYBunLkDVBV-k8jjZ7TN05HTI8PxQT9CXyw_ri6vq-tPy48XiujLN7ummY842smu5YJo1mlphHDcSQNCWAjBBLW2t47bTghvn5p3kwDroBHecCXaCXu91Nyn-mCCPqvfZQAh6gDhl1cp5sYLP_wvWxSkpalLAt3vQpJhzAqc2yfc6bRUlaheDKjGouxgK-_IgOnXFzQfy4HsBXh0AnY0OLunB-PzASU7mDdl9d7bnfvkA239fVKv3n_-ervYbPo_w-36j5KNawQRXX2-War26uVyuV7fqHfsDRMmu1Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21158720</pqid></control><display><type>article</type><title>Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Kulisevsky, Jaime ; Pascual-Sedano, Berta ; Barbanoj, Manel ; Gironell, Alexandre ; Pagonabarraga, Javier ; García-Sánchez, Carmen</creator><creatorcontrib>Kulisevsky, Jaime ; Pascual-Sedano, Berta ; Barbanoj, Manel ; Gironell, Alexandre ; Pagonabarraga, Javier ; García-Sánchez, Carmen</creatorcontrib><description>Mood fluctuations related to levodopa (LD) dosing are well‐known psychiatric complications of Parkinson's disease (PD). No formal studies explored how affective response to LD relates to the type of motor response to oral LD (stable or wearing‐off) and to different pharmacokinetic profiles of oral LD. We used an intrasubject randomized double‐blind crossover design to study 14 patients (7 stable, 7 wearing‐off) who were monitored for motor status, mood, anxiety, and plasma LD levels 1 hour before and 6 hours after an oral dose of immediate‐release (IR) and controlled‐release LD formulations. Analysis of the dose–response curves showed a significant interaction between the type of motor response and the type of LD. Only the wearing‐off patients had a significant mood elevation, and this effect was only significant following challenge with IR LD. Motor status strongly correlated with LD plasma levels and anxiety but not with mood ratings. Mood changes in PD patients are related to the patient's type of motor response to oral LD and also to the kinetic profile of the LD formulation used for dopaminergic replacement. © 2006 Movement Disorder Society</description><identifier>ISSN: 0885-3185</identifier><identifier>EISSN: 1531-8257</identifier><identifier>DOI: 10.1002/mds.21205</identifier><identifier>PMID: 17115388</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Administration, Oral ; Affect - drug effects ; Aged ; Antiparkinson Agents - administration & dosage ; Antiparkinson Agents - blood ; anxiety ; Anxiety - drug therapy ; Anxiety - etiology ; Biological and medical sciences ; Case-Control Studies ; Cross-Over Studies ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; dopamine ; Double-Blind Method ; Drug toxicity and drugs side effects treatment ; Female ; Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy ; Humans ; levodopa ; Levodopa - administration & dosage ; Levodopa - blood ; Male ; Medical sciences ; Middle Aged ; mood ; Nervous system (semeiology, syndromes) ; Neurology ; Pain Measurement ; Parkinson Disease - blood ; Parkinson Disease - drug therapy ; Parkinson Disease - physiopathology ; Parkinson's disease ; Pharmacology. Drug treatments ; Time Factors ; Toxicity: nervous system and muscle</subject><ispartof>Movement disorders, 2007-01, Vol.22 (1), p.62-67</ispartof><rights>Copyright © 2006 Movement Disorder Society</rights><rights>2007 INIST-CNRS</rights><rights>Copyright 2006 Movement Disorder Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4885-4b3fd48b6573a34a1d7cf5c8ee7161ee371d16df5dba75cff9b85e3beb75f5373</citedby><cites>FETCH-LOGICAL-c4885-4b3fd48b6573a34a1d7cf5c8ee7161ee371d16df5dba75cff9b85e3beb75f5373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmds.21205$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmds.21205$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,4025,27928,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18509409$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17115388$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kulisevsky, Jaime</creatorcontrib><creatorcontrib>Pascual-Sedano, Berta</creatorcontrib><creatorcontrib>Barbanoj, Manel</creatorcontrib><creatorcontrib>Gironell, Alexandre</creatorcontrib><creatorcontrib>Pagonabarraga, Javier</creatorcontrib><creatorcontrib>García-Sánchez, Carmen</creatorcontrib><title>Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study</title><title>Movement disorders</title><addtitle>Mov. Disord</addtitle><description>Mood fluctuations related to levodopa (LD) dosing are well‐known psychiatric complications of Parkinson's disease (PD). No formal studies explored how affective response to LD relates to the type of motor response to oral LD (stable or wearing‐off) and to different pharmacokinetic profiles of oral LD. We used an intrasubject randomized double‐blind crossover design to study 14 patients (7 stable, 7 wearing‐off) who were monitored for motor status, mood, anxiety, and plasma LD levels 1 hour before and 6 hours after an oral dose of immediate‐release (IR) and controlled‐release LD formulations. Analysis of the dose–response curves showed a significant interaction between the type of motor response and the type of LD. Only the wearing‐off patients had a significant mood elevation, and this effect was only significant following challenge with IR LD. Motor status strongly correlated with LD plasma levels and anxiety but not with mood ratings. Mood changes in PD patients are related to the patient's type of motor response to oral LD and also to the kinetic profile of the LD formulation used for dopaminergic replacement. © 2006 Movement Disorder Society</description><subject>Administration, Oral</subject><subject>Affect - drug effects</subject><subject>Aged</subject><subject>Antiparkinson Agents - administration & dosage</subject><subject>Antiparkinson Agents - blood</subject><subject>anxiety</subject><subject>Anxiety - drug therapy</subject><subject>Anxiety - etiology</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Cross-Over Studies</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>dopamine</subject><subject>Double-Blind Method</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Female</subject><subject>Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy</subject><subject>Humans</subject><subject>levodopa</subject><subject>Levodopa - administration & dosage</subject><subject>Levodopa - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>mood</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Neurology</subject><subject>Pain Measurement</subject><subject>Parkinson Disease - blood</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson Disease - physiopathology</subject><subject>Parkinson's disease</subject><subject>Pharmacology. Drug treatments</subject><subject>Time Factors</subject><subject>Toxicity: nervous system and muscle</subject><issn>0885-3185</issn><issn>1531-8257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUFvEzEQhS1ERUPhwB9AvgDisK29Xq-d3kKhKVJTKhHE0fLaY8ngXQd7F8i_x2lCe0KcZjT65s3oPYReUHJKCanPeptPa1oT_gjNKGe0kjUXj9GMSMkrRiU_Rk9z_kYIpZy2T9AxFaVjUs5QXJhpBAzOgRkzjg77vgfrdRnqwWIThzHFEMBWCQLoDDjAz2jjRuM44D5Gi_2Ab3X67occhzcZW5933DleYBunLkDVBV-k8jjZ7TN05HTI8PxQT9CXyw_ri6vq-tPy48XiujLN7ummY842smu5YJo1mlphHDcSQNCWAjBBLW2t47bTghvn5p3kwDroBHecCXaCXu91Nyn-mCCPqvfZQAh6gDhl1cp5sYLP_wvWxSkpalLAt3vQpJhzAqc2yfc6bRUlaheDKjGouxgK-_IgOnXFzQfy4HsBXh0AnY0OLunB-PzASU7mDdl9d7bnfvkA239fVKv3n_-ervYbPo_w-36j5KNawQRXX2-War26uVyuV7fqHfsDRMmu1Q</recordid><startdate>200701</startdate><enddate>200701</enddate><creator>Kulisevsky, Jaime</creator><creator>Pascual-Sedano, Berta</creator><creator>Barbanoj, Manel</creator><creator>Gironell, Alexandre</creator><creator>Pagonabarraga, Javier</creator><creator>García-Sánchez, Carmen</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope><scope>8BM</scope></search><sort><creationdate>200701</creationdate><title>Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study</title><author>Kulisevsky, Jaime ; Pascual-Sedano, Berta ; Barbanoj, Manel ; Gironell, Alexandre ; Pagonabarraga, Javier ; García-Sánchez, Carmen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4885-4b3fd48b6573a34a1d7cf5c8ee7161ee371d16df5dba75cff9b85e3beb75f5373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Administration, Oral</topic><topic>Affect - drug effects</topic><topic>Aged</topic><topic>Antiparkinson Agents - administration & dosage</topic><topic>Antiparkinson Agents - blood</topic><topic>anxiety</topic><topic>Anxiety - drug therapy</topic><topic>Anxiety - etiology</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Cross-Over Studies</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>dopamine</topic><topic>Double-Blind Method</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Female</topic><topic>Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy</topic><topic>Humans</topic><topic>levodopa</topic><topic>Levodopa - administration & dosage</topic><topic>Levodopa - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>mood</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Neurology</topic><topic>Pain Measurement</topic><topic>Parkinson Disease - blood</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson Disease - physiopathology</topic><topic>Parkinson's disease</topic><topic>Pharmacology. Drug treatments</topic><topic>Time Factors</topic><topic>Toxicity: nervous system and muscle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kulisevsky, Jaime</creatorcontrib><creatorcontrib>Pascual-Sedano, Berta</creatorcontrib><creatorcontrib>Barbanoj, Manel</creatorcontrib><creatorcontrib>Gironell, Alexandre</creatorcontrib><creatorcontrib>Pagonabarraga, Javier</creatorcontrib><creatorcontrib>García-Sánchez, Carmen</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>ComDisDome</collection><jtitle>Movement disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kulisevsky, Jaime</au><au>Pascual-Sedano, Berta</au><au>Barbanoj, Manel</au><au>Gironell, Alexandre</au><au>Pagonabarraga, Javier</au><au>García-Sánchez, Carmen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study</atitle><jtitle>Movement disorders</jtitle><addtitle>Mov. Disord</addtitle><date>2007-01</date><risdate>2007</risdate><volume>22</volume><issue>1</issue><spage>62</spage><epage>67</epage><pages>62-67</pages><issn>0885-3185</issn><eissn>1531-8257</eissn><abstract>Mood fluctuations related to levodopa (LD) dosing are well‐known psychiatric complications of Parkinson's disease (PD). No formal studies explored how affective response to LD relates to the type of motor response to oral LD (stable or wearing‐off) and to different pharmacokinetic profiles of oral LD. We used an intrasubject randomized double‐blind crossover design to study 14 patients (7 stable, 7 wearing‐off) who were monitored for motor status, mood, anxiety, and plasma LD levels 1 hour before and 6 hours after an oral dose of immediate‐release (IR) and controlled‐release LD formulations. Analysis of the dose–response curves showed a significant interaction between the type of motor response and the type of LD. Only the wearing‐off patients had a significant mood elevation, and this effect was only significant following challenge with IR LD. Motor status strongly correlated with LD plasma levels and anxiety but not with mood ratings. Mood changes in PD patients are related to the patient's type of motor response to oral LD and also to the kinetic profile of the LD formulation used for dopaminergic replacement. © 2006 Movement Disorder Society</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>17115388</pmid><doi>10.1002/mds.21205</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3185 |
| ispartof | Movement disorders, 2007-01, Vol.22 (1), p.62-67 |
| issn | 0885-3185 1531-8257 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68951659 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Administration, Oral Affect - drug effects Aged Antiparkinson Agents - administration & dosage Antiparkinson Agents - blood anxiety Anxiety - drug therapy Anxiety - etiology Biological and medical sciences Case-Control Studies Cross-Over Studies Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases dopamine Double-Blind Method Drug toxicity and drugs side effects treatment Female Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy Humans levodopa Levodopa - administration & dosage Levodopa - blood Male Medical sciences Middle Aged mood Nervous system (semeiology, syndromes) Neurology Pain Measurement Parkinson Disease - blood Parkinson Disease - drug therapy Parkinson Disease - physiopathology Parkinson's disease Pharmacology. Drug treatments Time Factors Toxicity: nervous system and muscle |
| title | Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T06%3A08%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20effects%20of%20immediate%20and%20controlled-release%20levodopa%20on%20mood%20in%20Parkinson's%20disease:%20A%20double-blind%20study&rft.jtitle=Movement%20disorders&rft.au=Kulisevsky,%20Jaime&rft.date=2007-01&rft.volume=22&rft.issue=1&rft.spage=62&rft.epage=67&rft.pages=62-67&rft.issn=0885-3185&rft.eissn=1531-8257&rft_id=info:doi/10.1002/mds.21205&rft_dat=%3Cproquest_cross%3E21158720%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21158720&rft_id=info:pmid/17115388&rfr_iscdi=true |